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arotid Plaque Assessment
Bumpy Road to
mproved Risk Prediction
e congratulate Nambi et al. (1) on their study of improved
rediction of coronary heart disease (CHD) risk by including the
nformation on carotid plaque presence in the ARIC (Atheroscle-
osis Risk In Communities) study. Inclusion of plaque in the risk
rediction model reclassified over 10% of individuals into the
igher risk category beyond the levels of carotid intima-media
hickness (CIMT) and traditional risk factors. The study is
ignificant because the ARIC investigators acknowledge that
mall, nonstenotic carotid plaque might be a different phenotype of
therosclerosis, carrying an important contribution to the vascular
isk beyond CIMT. Plaque presence was defined if 2 of the
ollowing 3 criteria were met: CIMT 1.5 mm, abnormal wall
hape, and abnormal wall texture. This is a somewhat novel
pproach, because Dr. Ward A. Riley (a reputable CIMT and
RIC investigator who unfortunately is no longer with us) believed
hat “whatever is between intima and media represents CIMT” (Dr.
ard A. Riley, personal communication, 2001). In the recent CIMT
eta-analysis (2) very little is mentioned regarding the difference
etween CIMT and plaque and the prognostic importance of carotid
laque. Carotid plaque is a distinctive phenotype of atherosclerosis,
ost likely is not a simple continuum of CIMT progression, and
redicts stroke and CHD risk better than CIMT (3).
Interestingly, the ARIC investigators report that slightly more
ubjects were reclassified to a lower risk group (approximately 12%)
han to a higher risk group (approximately 11%) after adding
IMT and plaque information. No one was reclassified from the
ow-risk group (5% estimated 10-year CHD risk) to the high-
isk group (20% estimated 10-year CHD risk). In the NOMAS
Northern Manhattan Study)—a prospective, multi-ethnic, urban,
opulation-based cohort—the presence of small, nonstenotic ca-
otid plaque reclassified 44% of the low-risk individuals (10%
stimated 10-year CHD risk) to the intermediate-risk category
10% to 20% estimated 10-year risk) (4). In addition, approxi-
ately 12% of subjects in a lower risk category had a 10-year
stimated risk of 25%, which reclassified these individuals to high
isk (20% estimated 10-year risk). None of the individuals was
eclassified to a lower risk category after adding information on
laque presence—as opposed to ARIC. The NOMAS results are,
owever, hardly ever cited, possibly because they appeared in
eurology, a journal mostly neglected by non-neurologists. There-
ore, “the intriguing hypothesis” raised by Stein and Johnson in the
ditorial Comment (5) that “carotid ultrasound could be used to
dentify persons at lower than apparent risk who might be
andidates for less intensive interventions” might be simply rejected
f data from NOMAS and others (6) are considered. sNevertheless, less intensive intervention should not be advised
ccording to ultrasound imaging data for individuals otherwise
stimated at intermediate-to-high vascular risk on the basis of
raditional vascular risk factors. We believe these individuals
hould be treated aggressively, irrespective of a possible lower risk
ccording to the information obtained by the levels of biomarkers,
ither imaging or soluble.
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eply
e thank Drs. Rohatgi and Berry and Rundek and Salameh for
heir interest in our communication regarding the use of carotid
ntima media thickness (CIMT) and plaque to improve coronary
eart disease (CHD) risk prediction in the ARIC (Atherosclerosis
isk In Communities) study (1).
It is important to note that our study tested whether CIMT and
laque can help better predict CHD risk, but it does not have the
bility to offer guidance on treatment strategies on the basis of such
risk prediction scheme. Therefore, we completely agree with Drs.
undek and Salameh that, on the basis of our data alone, one
hould not decide on decreasing interventions. However, we feel
hat such a strategy should be prospectively tested, as has been
uggested by Drs. Stein and Johnson in the editorial that accom-
anied our publication (2). Drs. Rundek and Salameh also discuss
heir excellent contribution from the NOMAS (Northern Man-
attan Study) (3), in which they examined the value of adding
laque to the Framingham risk prediction score (FRS). However,
ome important facts/differences need to be considered.
